Alkem Laboratories Limited has informed the Exchange that today i.e. on 23rd June, 2025, the sale and transfer of the Company s manufacturing facility in Madhya Pradesh stands completed in accordance with the conditions prescribed in the Business Transfer Agreement dated 06th January, 2025.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Midcap 150 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alkem Laboratories has completed the sale and transfer of its manufacturing facility located at the Special Economic Zone in Pithampur, Dhar, Madhya Pradesh to Rubicon Research Limited on a slump sale basis. The deal was originally signed via a Business Transfer Agreement on January 6, 2025, with an initial completion deadline of June 5, 2025, which was later extended to July 15, 2025. The transaction has now been finalized on June 23, 2025, in line with the conditions of the agreement. This follows Alkem's earlier intimation to the stock exchanges in January 2025 regarding the divestment.
The completion removes a manufacturing asset from Alkem's books, which may free up capital and simplify operations but could also impact future production capacity and revenue. Shareholders should watch for any disclosure on the sale proceeds and how the company plans to deploy the funds.